{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:34:04Z","timestamp":1760060044006,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clindermatol.2020.12.014","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T17:44:50Z","timestamp":1610387090000},"page":"64-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of primary cutaneous lymphomas during the COVID-19 pandemic"],"prefix":"10.1016","volume":"39","author":[{"given":"Valeria","family":"Mateeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Patsatsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.12.014_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2020.12.014_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.2584","article-title":"Cutaneous lymphomas\u2014an update 2019","volume":"37","author":"Kempf","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.2020.1097","article-title":"The novel coronavirus originating in Wuhan, China: challenges for global health governance","volume":"323","author":"Phelan","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0004","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard 2020. Available at: https:\/\/covid19.who.int\/. Accessed on 5 August 2020."},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0005","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0006","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41591-020-0920-6","article-title":"Addendum: estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China","volume":"26","author":"Wu","year":"2020","journal-title":"Nat Med"},{"year":"2020","series-title":"Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand","author":"Ferguson NM","key":"10.1016\/j.clindermatol.2020.12.014_bib0007"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0008","unstructured":"Centers for Disease Control and Prevention. Groups at Higher Risk for Severe Illness. 2020. Available at: www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/groups-at-higher-risk.html. Accessed on 5 August 2020."},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0010","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S0140-6736(20)30558-4","article-title":"Comorbidities and multi-organ injuries in the treatment of COVID-19","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0011","first-page":"1861","article-title":"Clinical characteristics of Covid-19 in China. Reply","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0012","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0013","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"year":"2018","series-title":"WHO Classification of Skin Tumours","author":"Elder","key":"10.1016\/j.clindermatol.2020.12.014_bib0014"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2020.04.049","article-title":"United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic","volume":"83","author":"Zic","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0016","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.16593","article-title":"Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines","volume":"34","author":"Papadavid","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0017","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cis844","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis."},{"year":"2020","series-title":"Short-term recommendations for the management of T-cell and primary cutaneous lymphomas during COVID-19","key":"10.1016\/j.clindermatol.2020.12.014_bib0018"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0019","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.24876","article-title":"Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Wilcox","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0021","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjd.13832","volume":"173","author":"Klemke","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0023","first-page":"e14042","article-title":"COVID-19 infection in patients with S\u00e9zary syndrome: report of two cases","author":"Gonzaga","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0024","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0025","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0026","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0027","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0028","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0029","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2133.2006.07428.x","article-title":"Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sezary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides","volume":"155","author":"Fraser-Andrews","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1523-1747.2000.00830.x","article-title":"Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides","volume":"114","author":"Fraser-Andrews","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0031","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2004-06-2220","article-title":"Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications","volume":"105","author":"Assaf","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0033","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0034","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome-Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0035","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0036","unstructured":"European Hematology Association scientific working group infections in Hematology. von Lilienfeld-Toal M, Vehreschild JJ CO, Pagano P, Compagno F, Hirsch HH. Frequently asked questions regarding SARS-CoV2 in cancer patients: Recommendations forclinicians caring for patients with malignant diseases 2020. Available at: https:\/\/ehaweb.org\/guidelines\/covid-19\/. Accessed on 5 August 2020."},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0037","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0038","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0190-9622(03)02488-5","article-title":"Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy","volume":"50","author":"Huber","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0039","article-title":"Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0041","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2 b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0042","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2 a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.clindermatol.2020.12.014_bib0043","doi-asserted-by":"crossref","first-page":"206S","DOI":"10.1111\/1523-1747.ep12875616","article-title":"Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma","volume":"95","author":"Zachariae","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0044","first-page":"809","article-title":"Low dose interferon-alpha2 b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group","volume":"84","author":"Rupoli","year":"1999","journal-title":"Haematologica"},{"issue":"6 Suppl","key":"10.1016\/j.clindermatol.2020.12.014_bib0045","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2 a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0046","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0047","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2 a in advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0048","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","article-title":"Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy","volume":"116","author":"Berger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0049","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1073>3.0.CO;2-R","article-title":"Induction of human tumor-loaded dendritic cells","volume":"91","author":"Berger","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0051","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0052","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1 H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leukemia Res"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0053","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0054","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0056","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0057","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0058","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0059","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3947\/ic.2020.52.1.110","article-title":"COVID-19, a clinical syndrome manifesting as hypersensitivity pneumonitis","volume":"52","author":"Song","year":"2020","journal-title":"Infect Chemother"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0061","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0062","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"American journal of hematology"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0063","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008908.pub2","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma","volume":"1","author":"Schlaak","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0064","first-page":"112","article-title":"S2 k-Leitlinie-Kutane Lymphome Update 2016-Teil 2: Therapie und Nachsorge (ICD10 C82-C86)","volume":"16","author":"Dippel","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0065","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0066","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0067","first-page":"1266","article-title":"S2 k-Leitlinie-Kutane Lymphome Update 2016-Teil 1: Klassifikation und Diagnostik (ICD10 C82-C86)","volume":"15","author":"Dippel","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2020.12.014_bib0068","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jhin.2020.01.022","article-title":"Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents","volume":"104","author":"Kampf","year":"2020","journal-title":"J Hosp Infect"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20302492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:07Z","timestamp":1760033827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20302492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0738081X20302492"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.014","relation":{},"ISSN":["0738-081X"],"issn-type":[{"type":"print","value":"0738-081X"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of primary cutaneous lymphomas during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}